Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2)

[Edit]

OCIA Domain Containing 2; Ovarian carcinoma immunoreactive antigen-like protein

Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2)
OCIAD2is highly expressed in adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component and is associated with better prognosis. TncRNA, OCIAD2, ANXA2, TMED4 and LGALS4 were expressed at significantly higher levels in invasive adenocarcinoma mixed subtype with BAC than in BAC.Only the OCIAD2 gene showed significantly higher expression in the tumor cells of invasive adenocarcinoma mixed subtype with BAC than in BAC. The patients with OCIAD2 expression showed a better clinical outcome than those without OCIAD2 expression, and OCIAD2 expression showed an inverse correlation with lymphatic invasion, blood vessel invasion and lymph node metastasis. OCIAD2 begins to express at the progression from in situ to invasive carcinoma, and is associated with the favorable prognosis of adenocarcinoma mixed subtype with BAC component.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPR870Hu01 Recombinant Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies MAR870Hu21 Monoclonal Antibody to Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) WB; IHC; ICC; IP.
PAR870Hu01 Polyclonal Antibody to Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) WB; IHC; ICC; IP.
Assay Kits SER870Hu ELISA Kit for Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) ELISA Kit Customized Service Offer
  1. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  2. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  3. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  4. "Lysine acetylation targets protein complexes and co-regulates major cellular functions."Science 325:834-840(2009) [PubMed] [Europe PMC] [Abstract]
  5. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  6. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]